Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The RAPS store will be under maintenance 15 January 2022 from 5 AM to 1 PM EST. Store functionality may be unavailable during this window.
We apologize for any inconvenience caused during this time.
Posted 03 June 2014 | By Alexander Gaffney, RAC,
The US Food and Drug Administration (FDA) has announced that it will soon classify surgical instruments intended to improve "the appearance of cellulite" as Class II medical devices, making it easier for them to be brought to market.
In the US, medical devices are regulated by FDA's Center for Devices and Radiological Health (CDRH) and subject to three general classifications:
While Class III devices almost always require the submission of a premarket application (PMA) and require prior approval, and Class I devices generally only require a company to notify FDA that a device is being marketed, Class II devices represent something of a compromise.
If FDA has set standards for a Class II device, sponsors must submit a premarket notification (usually referred to as a 510(k) application) certifying that the device meets both general controls to ensure device safety and efficacy and special controls meant to address the unique concerns of a specific type of device.
In return, FDA is able to grant marketing clearance to a device relatively quickly, avoiding the time-consuming PMA process, which generally takes a case-by-case approach to evaluating devices and requires the submission of clinical data.
The latest order, affecting Powered Surgical Instrument for Improvement in the Appearance of Cellulite, comes after a lengthy back-and-forth between FDA and Cabochon Aesthetics, Inc, which had submitted a request for classification to FDA.
In 2011, FDA had classified the device as a Class III medical device because it "was not substantially equivalent to a device that was introduced or delivered for introduction into interstate commerce" prior to the 1976 Medical Device Amendments to the Federal Food, Drug and Cosmetic Act.
Cabochon appealed FDA's decision, and pressed the agency to recognize its Cabochon System as a Class II device.
On 12 July 2013, FDA said it agreed, and issued an order that the device be classified as a Class II device.
Now the agency is opening up a similar avenue to all such devices, establishing special controls at 21 CFR 878.4790.
"Following the effective date of this final classification administrative order, any firm submitting a premarket notification (510(k)) for a powered surgical instrument for improvement in the appearance of cellulite will need to comply with the special controls named in the final administrative order," FDA explained.
The noted risks that must be controlled for include mechanical injury, infection, electrical shock, electromagenetic interference, adverse tissue reactions and use errors. As such, the following special controls must be established:
According to statements by Cabochon, the devices are minimally invasive and used to eliminate (by cutting) and vacuum out cellulite, similar to liposuction procedures. According to FDA's 510(k) clearance notice, the device is:
"A powered surgical instrument for improvement in the appearance of cellulite is a prescription device that is used for the controlled release of subcutaneous tissue for improvement in the appearance of cellulite. The device consists of a cutting tool powered by a motor and a means for instrument guidance to control the areas of subcutaneous tissue cutting underneath the cellulite depressions or dimples."
Federal Register Notice
Tags: Classification, Class II, Cellulite, Liposuction, Special Controls, 21 CFR 878.4790
Regulatory Focus newsletters
All the biggest regulatory news and happenings.